State of Wyoming Sells 16,142 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

State of Wyoming decreased its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 65.9% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 8,366 shares of the company’s stock after selling 16,142 shares during the period. State of Wyoming’s holdings in Teva Pharmaceutical Industries were worth $252,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the stock. Cetera Investment Advisers increased its position in shares of Teva Pharmaceutical Industries by 44.3% during the first quarter. Cetera Investment Advisers now owns 87,216 shares of the company’s stock valued at $2,627,000 after buying an additional 26,789 shares during the period. Militia Capital Management LLC bought a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $3,497,000. First Trust Advisors LP grew its stake in Teva Pharmaceutical Industries by 5.9% during the first quarter. First Trust Advisors LP now owns 9,619 shares of the company’s stock valued at $290,000 after acquiring an additional 539 shares in the last quarter. Barometer Capital Management Inc. purchased a new position in Teva Pharmaceutical Industries during the first quarter valued at approximately $2,343,000. Finally, PNC Financial Services Group Inc. increased its holdings in Teva Pharmaceutical Industries by 93.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 95,610 shares of the company’s stock worth $2,880,000 after acquiring an additional 46,206 shares during the period. Institutional investors own 54.05% of the company’s stock.

Insider Transactions at Teva Pharmaceutical Industries

In other news, CAO Amir Weiss sold 10,679 shares of the company’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the transaction, the chief accounting officer directly owned 20,016 shares in the company, valued at approximately $720,576. This represents a 34.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Richard Daniell sold 30,000 shares of the stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total value of $1,062,000.00. Following the transaction, the executive vice president owned 55,755 shares in the company, valued at $1,973,727. This trade represents a 34.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 444,673 shares of company stock worth $15,582,369. 0.54% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

TEVA has been the subject of several analyst reports. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Truist Financial upped their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Piper Sandler raised their price target on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Friday, July 17th. Finally, Barclays boosted their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $42.00.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Innovative medicines delivered strong growth. Teva said its key innovative brands grew 43% year over year in local-currency terms to more than $1 billion in second-quarter revenue. The company raised its 2026 outlook for all three key brands, supporting its strategy of shifting beyond lower-margin generics. Teva Delivers Strong Q2 Results and Raises Outlook
• Positive Sentiment: UZEDY momentum was particularly encouraging. U.S. sales of the long-acting schizophrenia treatment reached a record $77 million, up 43% year over year. Teva raised its 2026 UZEDY revenue forecast to $270 million-$290 million from $250 million-$280 million previously. UZEDY Record Q2 Net Sales and Outlook
• Positive Sentiment: Revenue guidance exceeded expectations. Teva forecast 2026 revenue of $16.5 billion-$16.9 billion, broadly aligned with the $16.7 billion consensus but described by investors as better than expected. Piper Sandler also raised its price target to $44 from $42 and maintained an Overweight rating. Teva Stock Rises After Earnings
• Neutral Sentiment: Options activity reflected increased bullish interest. Traders purchased 23,688 call options, approximately 136% above typical daily call volume. This may amplify short-term momentum, but it is not a fundamental indicator of business performance.
• Negative Sentiment: Quarterly profitability fell short. Teva reported second-quarter EPS of $0.02, below the $0.08 consensus and down from $0.66 a year earlier. Revenue of $4.14 billion exceeded estimates of $4.02 billion but declined roughly 1% year over year, primarily because of weaker generics revenue. Teva Quarterly Earnings Report
• Negative Sentiment: EPS guidance was below Wall Street expectations. Teva projected 2026 EPS of $1.91-$2.11 versus the $2.17 consensus, creating a counterweight to the improved revenue outlook and strong branded-drug performance.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $34.55 on Thursday. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. The stock has a market cap of $39.73 billion, a P/E ratio of 25.98, a price-to-earnings-growth ratio of 3.35 and a beta of 0.86. The firm’s fifty day moving average price is $33.19 and its 200-day moving average price is $32.69.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. On average, equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.